Wincap Financial LLC Lowers Stock Holdings in CVS Health Corporation $CVS

Wincap Financial LLC cut its holdings in CVS Health Corporation (NYSE:CVS) by 86.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,672 shares of the pharmacy operator’s stock after selling 17,761 shares during the quarter. Wincap Financial LLC’s holdings in CVS Health were worth $212,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in CVS. Norges Bank purchased a new stake in CVS Health in the 2nd quarter worth $1,358,698,000. Wellington Management Group LLP lifted its holdings in CVS Health by 391.6% during the third quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock valued at $477,273,000 after purchasing an additional 5,042,816 shares in the last quarter. Amundi grew its position in shares of CVS Health by 95.3% in the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after purchasing an additional 3,637,943 shares during the period. Invesco Ltd. increased its stake in shares of CVS Health by 15.3% during the second quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after purchasing an additional 3,118,626 shares in the last quarter. Finally, Capital Research Global Investors raised its position in shares of CVS Health by 24.5% during the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after purchasing an additional 2,253,531 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

NYSE:CVS opened at $70.08 on Friday. CVS Health Corporation has a one year low of $58.35 and a one year high of $85.15. The stock has a market cap of $89.16 billion, a PE ratio of 50.79, a P/E/G ratio of 0.74 and a beta of 0.49. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. The stock has a 50 day moving average price of $76.62 and a 200 day moving average price of $77.73.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The company had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities research analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Investors of record on Thursday, April 23rd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.8%. CVS Health’s dividend payout ratio is currently 192.75%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a research note on Wednesday, December 10th. Wolfe Research reduced their target price on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Robert W. Baird raised their target price on CVS Health from $82.00 to $92.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. The Goldman Sachs Group lifted their price target on CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Finally, UBS Group reissued an “outperform” rating on shares of CVS Health in a research note on Wednesday, December 10th. Twenty equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.05.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.